XML 72 R58.htm IDEA: XBRL DOCUMENT

DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	12 Months Ended
DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Components of research and drug development operations presented on the condensed consolidated statements of operations
Loss from discontinued operations, basic	$ 0	$ 0	$ (94,934)
Theravance Biopharma Spinoff
Components of research and drug development operations presented on the condensed consolidated statements of operations
Net revenues			3,129
Loss from discontinued operations, basic			$ (94,934)

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details